Needham initiated coverage of Centessa (CNTA) with a Buy rating and $35 price target Centessa’s ORX750 has a potentially best-in-class clinical profile based on its preclinical and healthy volunteers data, broad therapeutic index, and flexible Phase 2a design, allowing it to leverage learnings from competitors to identify doses to take into pivotal trials, the analyst tells investors in a research note. Needham believes ORX750 has the potential to grow to over $1.8B by 2030 and more than $3B in 2035 due to its likely best-in-class clinical profile than can offer a single drug with multiple doses to tailor to patients across the three indications, and believes Centessa is in a strong position to tap into the potential for this class beyond the three initial indications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Positive Outlook on Centessa Pharmaceuticals Driven by ORX750’s Promising Potential and Market Growth
- Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
- Centessa reports Q1 EPS (20c) vs (38c) last year
- Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue